StockData
Rezolute, Inc. logo

Rezolute, Inc. (RZLT) stock

RZLTNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$4.01+0.43 (+12.15%)

Close on Nov 17, 2026Market cap $388.34MP/E –Yield –

Rezolute r&d expenses

Research and development expenses are spending on new products and technology.

Rezolute's R&D Expenses for the twelve months ending Sep 30, 2026 was $53.46M, down 13.7% year over year. For fiscal 2026 it was $53.80M, down 12.6% from the year before. Over ten years it grew 19.0% a year on average. The highest annual figure on record is $61.53M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Jun 30, 2026$53.80M-12.6%
FY2025Jun 30, 2025$61.53M+10.4%
FY2024Jun 30, 2024$55.74M+27.2%
FY2023Jun 30, 2023$43.81M+34.9%
FY2022Jun 30, 2022$32.49M+116.8%
FY2021Jun 30, 2021$14.99M+3.7%
FY2020Jun 30, 2020$14.45M-24.3%
FY2019Jun 30, 2019$19.08M+10.4%
FY2018Jun 30, 2018$17.28M+42.9%
FY2017Jun 30, 2017$12.09M+28.0%
FY2016Jun 30, 2016$9.45M+101.0%
FY2015Jun 30, 2015$4.70M+13599.4%
FY2014Jun 30, 2014$34.32K–
FY2011Dec 31, 2011$0–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ3 2026Sep 30, 2026$12.81M-2.6%
Q4 FY2026CQ2 2026Jun 30, 2026$14.89M-28.6%
Q3 FY2026CQ1 2026Mar 31, 2026$11.41M-25.3%
Q2 FY2026CQ4 2025Dec 31, 2025$14.35M+13.6%
Q1 FY2026CQ3 2025Sep 30, 2025$13.15M+3.1%
Q4 FY2025CQ2 2025Jun 30, 2025$20.86M+9.3%
Q3 FY2025CQ1 2025Mar 31, 2025$15.28M+23.2%
Q2 FY2025CQ4 2024Dec 31, 2024$12.63M+4.9%
Q1 FY2025CQ3 2024Sep 30, 2024$12.75M+4.4%
Q4 FY2024CQ2 2024Jun 30, 2024$19.09M+74.6%
Q3 FY2024CQ1 2024Mar 31, 2024$12.40M-12.9%
Q2 FY2024CQ4 2023Dec 31, 2023$12.04M+10.0%
Q1 FY2024CQ3 2023Sep 30, 2023$12.21M+58.5%
Q4 FY2023CQ2 2023Jun 30, 2023$10.93M+27.5%
Q3 FY2023CQ1 2023Mar 31, 2023$14.23M+63.8%
Q2 FY2023CQ4 2022Dec 31, 2022$10.95M+15.8%
Q1 FY2023CQ3 2022Sep 30, 2022$7.70M+33.4%
Q4 FY2022CQ2 2022Jun 30, 2022$8.57M+95.4%
Q3 FY2022CQ1 2022Mar 31, 2022$8.69M+131.1%
Q2 FY2022CQ4 2021Dec 31, 2021$9.45M+110.2%
Q1 FY2022CQ3 2021Sep 30, 2021$5.77M+146.3%
Q4 FY2021CQ2 2021Jun 30, 2021$4.39M+79.5%
Q3 FY2021CQ1 2021Mar 31, 2021$3.76M+0.7%
Q2 FY2021CQ4 2020Dec 31, 2020$4.50M-10.8%
Q1 FY2021CQ3 2020Sep 30, 2020$2.34M-27.5%
Q4 FY2020CQ2 2020Jun 30, 2020$2.45M-65.4%
Q3 FY2020CQ1 2020Mar 31, 2020$3.73M+49.5%
Q2 FY2020CQ4 2019Dec 31, 2019$5.04M+47.6%
Q1 FY2020CQ3 2019Sep 30, 2019$3.23M-25.0%
Q4 FY2018CQ2 2018Jun 30, 2018$7.06M+128.2%
Q3 FY2018CQ1 2018Mar 31, 2018$2.50M-27.4%
Q2 FY2018CQ4 2017Dec 31, 2017$3.41M+11.0%
Q1 FY2018CQ3 2017Sep 30, 2017$4.31M+73.4%
Q4 FY2017CQ2 2017Jun 30, 2017$3.09M+16.9%
Q3 FY2017CQ1 2017Mar 31, 2017$3.44M+48.9%
Q2 FY2017CQ4 2016Dec 31, 2016$3.08M–
Q1 FY2017CQ3 2016Sep 30, 2016$2.49M–
Q4 FY2016CQ2 2016Jun 30, 2016$2.65M–
Q3 FY2016CQ1 2016Mar 31, 2016$2.31M–

More Rezolute figures

See a number that looks wrong?